title: Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors.
abstract: The rapid recovery of hematopoiesis after allogeneic blood stem cell transplantation has been attributed to the quality and quantity of hematopoietic progenitors in the blood stem cell grafts from filgrastim-stimulated donors. To determine whether further stimulation with filgrastim after transplantation would affect hematopoietic recovery, a prospective, randomized, controlled study was performed. Forty-two adult recipients of allogeneic blood stem cells from human leukocyte antigen-matched related donors were randomized to receive 10 microg/kg per day filgrastim subcutaneously from day 1 through neutrophil recovery or no growth factor support after transplantation. There was no significant difference between the 2 groups in the number of CD34(+) cells infused (median, 4.8 vs 4.3 x 10(6)/kg). Graft-versus-host (GVHD) disease prophylaxis consisted of tacrolimus and steroids for 9 patients and tacrolimus and minimethotrexate for 33 patients. The group receiving filgrastim had a shorter time to neutrophil levels greater than 0.5 x 10(9)/L (day 12 vs day 15, P =.002) and to neutrophil levels greater than 1.0 x 10(9)/L (day 12 vs day 16, P =.01). The filgrastim group also had a trend for earlier discharge (day 16 vs 20, P =.05). There was no significant difference between the groups in time to platelet recovery, number of transfusions, regimen-related toxicity, infection, incidence of GVHD, relapse, survival, or hospital charges. It can be concluded that the administration of filgrastim after allogeneic blood stem cell transplantation shortens the time to neutrophil recovery. (Blood. 2001;97:3405-3410)
authors.affiliation: Baylor College of Medicine, Center for Cell and Gene Therapy, The University of Texas M. D. Anderson Cancer Center, 6565 Fannin Street, Houston, TX 77030, USA. donnap@bcm.tmc.edu
authors.forename: D
authors.initials: D
authors.lastname: Przepiorka
authors.forename: T L
authors.initials: TL
authors.lastname: Smith
authors.forename: J
authors.initials: J
authors.lastname: Folloder
authors.forename: P
authors.initials: P
authors.lastname: Anderlini
authors.forename: K W
authors.initials: KW
authors.lastname: Chan
authors.forename: M
authors.initials: M
authors.lastname: Körbling
authors.forename: B
authors.initials: B
authors.lastname: Lichtiger
authors.forename: F
authors.initials: F
authors.lastname: Norfleet
authors.forename: R
authors.initials: R
authors.lastname: Champlin
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects*; D018380:Hematopoietic Stem Cell Transplantation; D006650:Histocompatibility Testing; D017721:Hospital Costs; D006801:Humans; D007239:Infections / Q000453:epidemiology; D007938:Leukemia / Q000628:therapy; D007958:Leukocyte Count; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy; D009504:Neutrophils; D010976:Platelet Count; D011446:Prospective Studies; D011994:Recombinant Proteins; D012008:Recurrence; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim